|
RE-104
RE104, formerly known as FT-104, and as 4-glutaryloxy-''N'',''N''-diisopropyltryptamine (4-HO-DiPT ''O''-glutarate or 4-GO-DiPT), is an investigational drug product being developed by the pharmaceutical company Reunion Neuroscience. RE104 a prodrug ester of a synthetic psychedelic 4-hydroxytryptamine, 4-HO-DiPT. It is one of a number of related psychedelic derivatives being developed as pharmaceuticals to treat mood disorders. RE104 is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression. As of 2024, RE104 entered a Phase II clinical trial for post-partum depression. Pharmacology RE104 is a prodrug that is converted into the psychedelic tryptamine 4-HO-DiPT upon administration. 4-OH-DiPT s chemically related to the neurotransmitter serotonin and acts as a non-selective agonist of the serotonin receptors. 4-OH-DiPT acts as an agonist on the serotonin 2A receptor (Ki 120 nM). Activation of one serotonin receptor, th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Reunion Neuroscience
Field Trip Health was a Canadian Ketamine-assisted psychotherapy company, founded in April 2019. In May 2022, the company split into two separate, independent entities: Field Trip Health and Wellness and Reunion Neuroscience. Field Trip Health and Wellness is now defunct with its assets acquired by two different companies, while Reunion Neuroscience is still active as of 2024, continuing the development of the psychedelic compound FT-104. History Field Trip Health was founded in April 2019 by Ronan Levy, Joseph del Moral, Hannan Fleiman, Ryan Yermus and Mujeeb Jafferi. All of the cofounders, except for Jafferi, previously worked together in the Canadian cannabis industry. The company was developing the psychedelic molecule, FT-104. The compound targeted the 5-HT2A receptor in the brain, the same receptor that psilocybin targets, and intended to produce a hallucinogenic effect that lasted roughly two hours, or approximately half the time a psychedelic experience with magic ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MSP-1014
MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.Araujo JA, Higgins GA, de Lannoy IA, Dean I, Atkinson J, Lanthier J, Slassi M. (2022 November 13). 147.05 / JJ5 - The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Neuroscience 2022. https://www.abstractsonline.com/pp8/#!/10619/presentation/70912 It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical. As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders. The chemical structure of MSP-1014 does not yet seem to have been disclosed. However, Mindse ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
EB-002
EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders. It is taken by mouth. The drug is under development by Enveric Biosciences. As of November 2024, it is in the preclinical research stage of development. In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62million. Its exact chemical structure does not yet appear to have been disclosed. See also * List of investigational hallucinogens and entactogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmenta ... * RE-109 * RE-104 * MSP-1014 Ref ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
RE-109
''O''-Glutarylpsilocin (developmental code name RE109), also known as 4-glutaryloxy-''N'',''N''-dimethyltryptamine (4-HO-DMT ''O''-glutarate) is a serotonergic psychedelic of the tryptamine family. It acts as a prodrug of psilocin (4-HO-DMT) similarly to other psilocin prodrugs like 4-AcO-DMT, 4-PrO-DMT, and psilocybin (4-PO-DMT). The drug is bond cleavage, cleaved into psilocin by non-specific esterases. ''O''-Glutarylpsilocin was first described in the scientific literature in 2024. It has been patented by Reunion Neuroscience. A related drug, RE-104 (4-GO-DiPT), a prodrug A prodrug is a pharmacologically inactive medication or compound that, after intake, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Instead of administering a drug directly, a corresponding prodrug can be ... of 4-HO-DiPT, is being developed for potential medical use. See also * List of investigational hallucinogens and entactogens * EB-002 * MSP-1014 References E ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
List Of Investigational Hallucinogens And Entactogens
This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.'' The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic serotonin 5-HT2A receptor agonists and non-hallucinogenic ketamine analogues. Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in October 2024. It is likely to become outdated with time. Under development Preregistration * Midomafetamine (MDMA ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Serotonin 2A Receptor
The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and functions as a G protein-coupled receptor (GPCR). It is a cell surface receptor that activates multiple intracellular signalling cascades. Like all 5-HT2 receptors, the 5-HT2A receptor is coupled to the Gq/G11 signaling pathway. It is the primary excitatory receptor subtype among the serotonin-responsive GPCRs. The 5-HT2A receptor was initially noted for its central role as the primary target of serotonergic psychedelic drugs such as LSD and psilocybin mushrooms. It later regained research prominence when found to mediate, at least in part, the effects of many antipsychotic drugs, particularly atypical antipsychotics. Downregulation of post-synaptic 5-HT2A receptors is an adaptive response triggered by chronic administration of selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics. Elevated 5-HT2A receptor density has been observed in suicidal and oth ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Designer Drugs
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union, Australia, and New Zealand, as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these designer drugs were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects and shorter duration (and possibly also because it is easier to apply for patents for new molecules) and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human tr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
THC Hemisuccinate
THC hemisuccinate (Δ9-THC-O-hemisuccinate, Dronabinol hemisuccinate) is a synthetic derivative of tetrahydrocannabinol, developed in the 1990s. It is a water-soluble prodrug ester which is converted into THC inside the body, and was developed to overcome the poor bioavailability of THC when taken by non-inhaled routes of administration. In medical applications it has mainly been formulated as rectal suppositories. See also * THC methylcarbonate * THC-O-acetate * THC-O-phosphate * THC-VHS THC valine hemisuccinate (THC-VHS, NB-1111, SBI-100) is a synthetic prodrug of tetrahydrocannabinol, developed at the University of Mississippi as a stabilised formulation for ophthalmic administration, for use in the treatment of glaucoma and ... * SP-111 References Benzochromenes Cannabinoids {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
4-PrO-DMT
4-Propionoxy-''N,N''-dimethyltryptamine (4-PrO-DMT, or O-Propionylpsilocin) is a synthetic psychedelic drug from the tryptamine family with psychedelic effects, and is believed to act as a prodrug for psilocin. It produces a head-twitch response in mice. It has been sold online as a designer drug since May 2019. It was first identified as a new Psychoactive drug, psychoactive substance in Sweden, in July 2019. A number of related derivatives have been synthesized as prodrugs of psilocin for medical applications. Recreational use Dosage 4-PrO-DMT is reported to be orally Psychoactive drug, psychoactive substance and while dosage effects have been studied in mice, its effects and longevity on humans has not been formally studied. The effects of 4-PrO-DMT are similar to those of psilocin (4-HO-DMT), as it acts as a prodrug. Toxicity Very little data about the toxicity or pharmacology of 4-PrO-DMT is known. Its chemical structure and Pharmacology, pharmacological activity are ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
4-AcO-DiPT
4-Acetoxy-DiPT, also known as 4-acetoxy-''N'',''N''-diisopropyltryptamine or as ipracetin, is a synthetic psychedelic tryptamine. It is relatively uncommon and has only a short history of human use. Interactions Chemistry 4-AcO-DiPT is a tryptamine structurally similar to 4-HO-DiPT and psilocin. Legal status Denmark 4-AcO-DiPT is added to the list of Schedule B controlled substances. Japan 4-Acetoxy-DiPT is a controlled substance in Japan. Sweden ''Sveriges riksdags'' health ministry ''Statens folkhälsoinstitut'' classified 4-AcO-DiPT as "health hazard" under the act ''Lagen om förbud mot vissa hälsofarliga varor'' (translated ''Act on the Prohibition of Certain Goods Dangerous to Health'') as of Mar 1, 2005, in their regulation SFS 2005:26 listed as 4-acetoxi-N,N-diisopropyltryptamin (4-AcO-DIPT), making it illegal to sell or possess. United States 4-Acetoxy-DiPT is an unscheduled substance in the United States. Due to similarities to other scheduled tryptamines, su ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Duration Of Action
Pharmacodynamics (PD) is the study of the biochemical and physiologic effects of drugs (especially pharmaceutical drugs). The effects can include those manifested within animals (including humans), microorganisms, or combinations of organisms (for example, infection). Pharmacodynamics and pharmacokinetics are the main branches of pharmacology, being itself a topic of biology interested in the study of the interactions of both endogenous and exogenous chemical substances with living organisms. In particular, pharmacodynamics is the study of how a drug affects an organism, whereas pharmacokinetics is the study of how the organism affects the drug. Both together influence dosing, benefit, and adverse effects. Pharmacodynamics is sometimes abbreviated as PD and pharmacokinetics as PK, especially in combined reference (for example, when speaking of PK/PD models). Pharmacodynamics places particular emphasis on dose–response relationships, that is, the relationships between drug con ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
